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Abstract
Background: Amodiaquine is frequently used as a partner drug in combination therapy or in some
setting as monotherapy, but little is known about its effects on gametocyte production and sex ratio
and its potential influence on transmission in Africa. The effects of amodiaquine on sexual stage
parasites and gametocyte sex ratio, and the factors associated with a male-biased sex ratio were
evaluated in 612 children with uncomplicated Plasmodium falciparum malaria who were treated with
amodiaquine during the period 2000 – 2006 in an endemic area.
Methods: Clinical, parasitological and laboratory parameters were evaluated before treatment and
during follow-up for 28–42 days, and according to standard methods. Gametocyte sex ratio was
defined as the proportion of peripheral gametocytes that are male.
Results: Clinical recovery from illness occurred in all children. Gametocytaemia was detected in
66 patients (11%) before treatment and in another 56 patients (9%) after treatment. Gametocyte
densities were significantly higher by days 3–7 following treatment compared with pre-treatment
(P < 0.0001). Overall, mean gametocyte sex ratio increased significantly during follow-up and over
the study periods from 2000–2006 (P < 0.001 in both cases), but was female-biased at enrolment
throughout the study periods. Absence of fever, a haematocrit < 25%, asexual parasitaemia >
20,000/μL, gametocytaemia < 18/μL, and enrolment in 2006 were associated with a male-biased
sex ratio pre-treatment. Anaemia and high parasitaemia were independent predictors of
gametocyte maleness 7 days post treatment.
Conclusion: Amodiaquine may significantly increase gametocyte carriage, density and sex ratio,
and may potentially influence transmission. It is possible that anaemia could have contributed to the
increased sex ratio. These findings may have implications for malaria control efforts in Africa.
Background
Amodiaquine, a Manic base related to chloroquine, is
considered a safe drug for the treatment of acute, uncom-
plicated, Plasmodium falciparum malaria [1], and is increas-
ingly used as partner drug for artemisinin [2-7] and non-
artemisinin based [8-10] combination therapies. Studies
have shown that antimalarials modify gametocyte car-
riage and influence malaria transmission [7,11-14], sug-
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gesting careful consideration in the selection of partner
drugs in combination therapies.
Despite similarity and superior efficacy to chloroquine,
increasing use in Africa, and the suggestion that mutations
conferring resistance to chloroquine may confer resistance
to amodiaquine in Africa [15,16], little is known of the
effects of amodiaquine on gametocyte carriage and sex
ratio, and its potential influence on transmission in Afri-
can children. Such a study is necessary as it may poten-
tially harness the efforts to control drug resistance and
prolong the use of combination therapies in the commu-
nity.
The aims of the present study were to: determine the
effects of amodiaquine on asexual-stage parasites, game-
tocyte carriage and sex ratio; and evaluate the factors that
influence the production of a male-biased sex ratio in chil-
dren presenting with acute, symptomatic, uncomplicated
P. falciparum malaria before and following treatment with
amodiaquine in an endemic area.
Patients and methods
Patients
The study was conducted in children aged ≤ 12 years with
acute, uncomplicated, P. falciparum malaria in Ibadan, a
malaria endemic area in southwestern Nigeria [17]. Fully
informed consent was obtained from the parents/guardi-
ans of each child. Inclusion criteria were: fever or history
of fever in the 24–48 h preceding presentation, pure P. fal-
ciparum parasitaemia ≥ 2,000 asexual forms/μL, absence
of other concomitant illness, no history of antimalarial
use in the 2 weeks preceding presentation, and negative
urine tests for antimalarial drugs (Dill-Glazko and lignin).
Patients with severe malaria [18], severe malnutrition,
serious underlying diseases (renal, cardiac, or hepatic),
and known allergy to study drug were excluded from the
study. The study was approved by the Ethics Committee of
the Ministry of Health, Ibadan, Nigeria.
Drug management
After clinical assessment, blood was obtained for haemat-
ocrit determination and for quantification of asexual and
sexual parasitaemia. Patients were treated with 25–30 mg/
kg of amodiaquine base (Camoquine®) given orally over
3 days. All patients waited for at least 3 h after to ensure
the drug was not vomited. If it was, the patient was
excluded form the study.
Oral paracetamol (acetaminophen) at 10–15 mg/kg 6–8
hourly was given for 12–24 h if body temperature was >
38°C. Patients were seen daily, at approximately the same
time of the day for the first four days (days 0–3) and then
daily on days 7, 14, 21, 28, 35 and 42 after treatment had
begun. At each visit, patients were assessed clinically, and
thick and thin blood smears were obtained for quantifica-
tion of parasitaemia. The fever clearance time (FCT) was
defined as the time taken for the body temperature to fall
below 37.5°C and remain below this value for > 48 h.
Laboratory investigations
Asexual parasite and gametocyte counts were measured
daily for the first four days (days 0–3) and thereafter on
days 7, 14, 21, 28, 35 and 42. Quantification in Giemsa-
stained thick blood films was undertaken against 500 leu-
kocytes in the case of asexual parasitaemia, and against
1000 leukocytes in the case of gametocytes, and from this
figure, the parasite density was calculated assuming a leu-
kocyte count of 6,000/μL of blood. Parasite clearance time
(PCT) was the time interval from the start of antimalarial
treatment until the asexual parasite count fell below the
detectable levels in a peripheral blood smear. Capillary
blood, collected before and during follow-up, was used to
measure packed cell volume (PCV). PCVs were measured
using a microhaematocrit tube and microcentrifuge
(Hawksley, Lancing, UK). Routine haematocrit was
undertaken on days 0, 3, 7, 14, 21, 28, 35 and 42. Blood
was spotted on filter papers on days 0, 1, 3, 7, 14, 21, 28,
35 and 42 and at the time of re-appearance of peripheral
parasitaemia after its initial clearance for parasite genotyp-
ing. Molecular genotyping was carried out as previously
described [16].
Determination of gametocyte sex ratio
Gametocyte sex determination was based on the follow-
ing criteria [19,20]: males (microgametocytes) are smaller
than females (macrogametocytes), the nucleus is larger in
males than females, the ends of the cells are rounder in
males and angular in females, with Giemsa the cytoplasm
stains purple in males and deep blue in females, and the
granules of malaria pigment are centrally located females
and more widely scattered in males. The sex ratio was
defined as the proportion of gametocytes in peripheral
blood that were male [21]. Gametocytes were sexed if the
gametocyte density was ≥ 10/μL blood.
Data analysis
Data were analyzed using version 6 of the Epi-Info soft-
ware [22] and the statistical programme SPSS for Win-
dows version 10.01 [23]. Variables considered in the
analysis were related to the densities of P. falciparum
gametocytes and trophozoites. Proportions were com-
pared by calculating χ2 with Yates' correction or by Fisher
exact or by Mantel Haenszel tests. Normally distributed,
continuous data were compared by Student's t-tests and
analysis of variance (ANOVA). Data not conforming to a
normal distribution were compared by the Mann-Whit-
ney U-tests and the Kruskal-Wallis tests (or by Wilcoxon
ranked sum test). Kaplan-Meier plots are also presented to
compare gametocyte carriage rates, and the duration ofMalaria Journal 2008, 7:169 http://www.malariajournal.com/content/7/1/169
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carriage of a male biased gametocyte sex ratio following
treatment in those who were gametocytaemic at presenta-
tion. Differences in survival time were assessed by inspec-
tion of Kaplan-Meier curves and log-rank tests. The
relationship between gametocyte sex ratio and gameto-
cyte or asexual parasite density was assessed by linear
regression. A multiple logistic regression model was used
to test the association between a male biased sex ratio,
that is, sex ratio ≥ 0.5 (yes or no at presentation or during
follow up) and factors that were significant at univariate
analysis: presence of fever, haematocrit < 25%, asexual
parasitaemia > 20,000/μL, and gametocytaemia < 18/μL.
Because the study was conducted over a period of six and
a half year, time in years since the commencement of the
study was included as a covariate in the model for pre-
treatment male-biased sex ratio. All tests of significance
were two-tailed. P-values of ≤ 0.05 were taken to indicate
significant differences. Data were (double)-entered seri-
ally using the patients' codes and were only analyzed at
the end of the study.
Results
Baseline characteristics of patients at enrolment
Between September 2000 and December 2006, 615 chil-
dren (297 males, 318 females) with P. falciparum malaria,
aged between 0.5–12 years (mean ± standard deviation
[SD] = 6.5 ± 3.2 years) were enrolled. Of these, 612 (294
males, 318 females) completed at least 28 days of follow
up and were analyzed (Table 1). The characteristics of the
children were similar during the study periods except for
the geometric mean parasite density that was significantly
higher in 2006 than in 2000 and 2004 (P < 0.0001) (Table
1).
Clinical responses
All children responded promptly to treatment, and none
developed severe malaria. The overall mean (range) FCT
was 1.1 (SEM 0.02) d, and was not significantly different
between the years of enrolment (Table 1). None of the
studied children had significant adverse effects as moni-
tored by clinical symptoms, but overall, 46 children
reported pruritus, which did not interfere with sleep.
Parasitological responses
The overall mean PCT (SEM) was 2.7 (0.005) d and was
not significantly different during the study periods (Table
1). Recrudescent infections confirmed by polymerase
chain reaction (PCR) occurred in 25 children: in 6, 8, and
11 children in 2000, 2004, and 2006, respectively. The
characteristics of the recrudescent infections will be
reported elsewhere.
Gametocytaemia
Gametocytes were detected in peripheral blood in 122
(20%) children (in 66 children before treatment and in 56
children after initiation of treatment) (Table 2). Gameto-
cyte detection rates before, during and after treatment
were similar during the study periods (Table 3). Gameto-
cyte densities during the study periods are summarized in
Table 3. Overall, gametocytaemia increased significantly
Table 1: Overall baseline characteristics and immediate therapeutic response of the children enrolled into the study, and by year of 
enrolment
Year
2000 2004 2006 2000–2006
Enrolled N 105 390 120 615
Gender F/M 53/52 195/195 70/50 318/297
Age (years) Mean 5.6 6.7 6.7 6.5
SD 2.7 3.3 3.2 3.2
Weight (kg) Mean 15.6 18.1 18.6 17.8
SD 4.9 7.1 6.8 6.8
Packed cell volume (%) Mean 29.8 30 31.2 30.3
SD 3.9 3.9 3.9 3.9
Duration of illness (days) Mean 2.9 2.9 2.9 2.9
SD 1.2 1.2 1.1 1.2
Temperature (°C) Mean 38.2 38.2 38.1 38.1
SD 1.2 1.2 1.2 1.2
Asexual parasitaemia (/μL) GM 21,261 21,468 68,839* 26,908
Gametocytaemia (/μL) GM 13 15 17 15
Parasite clearance time (days) Mean 2.6 2.6 2.8 2.7
SD 0.8 0.7 1.7 1.3
Fever clearance time (days) Mean 1.1 1.1 1.1 1.1
SD 0.4 0.4 0.3 0.4
*P = < 0.0001
SD, standard deviation; GM, geometric mean.Malaria Journal 2008, 7:169 http://www.malariajournal.com/content/7/1/169
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by days 3–7 during follow up (P < 0.0001) but did not dif-
fer between the study periods.
Duration of gametocyte carriage in children with 
gametocytaemia at enrolment
The probability of a mosquito infectivity following a
blood meal is related to gametocyte density and the dura-
tion of carriage by the host. Figure 1 is a Kaplan-Meier plot
(survival curve) of the cumulative probability of remain-
ing gametocyte free following treatment with amodi-
aquine during the study periods. The probabilities were
similar during the periods of the study (Log rank statistic
= 0.8, P = 0.23).
Temporal changes in gametocyte sex ratio
In 122 children who were gametocytaemic at presentation
or during follow up, a total of 2,286, 2,197, 3,108, 4,676,
2,880, 618, 54 and 576 gametocytes were counted on
days 0, 1, 2, 3, 7, 14, 21, and 28, respectively. Of these,
2,050, 1,986, 2,843, 4,518, 2,699, 600, 54, and 440 game-
tocytes could be sexed on days 0, 1, 2, 3, 7, 14, 21, and 28,
respectively. The corresponding number of patients in
whom the gametocytes were counted was 66, 49, 47, 70,
50, 29, 5, and 4, respectively.
Following treatment with amodiaquine, gametocyte sex
ratio increased significantly over the course of the infec-
tion. (Figure 2 and Table 4): 7.6% of the gametocytes were
male at day 0, 25% at day 3, and 29% at day 7 (X2 = 15.2,
P = 0.0005). Gametocyte sex ratio at enrolment increased
significantly during the study periods: the ratio was 0.4%
in 2000, 4.8% in 2004, and 20% in 2006 (P < 0.0001),
although it was still largely female-biased (Table 4). The
variations in haematocrit, density of gametocyte and
gametocyte sex ratio are shown in Figure 2. During the
first week of follow up, gametocyte sex ratio increased as
the packed cell volume decreased and the gametocyte
density increased, suggesting that the latter may have been
a direct contribution of the effect of amodiaquine on sex
ratio, since, in general, low but not relatively high game-
tocytaemia is associated with male-biased sex ratio.
The possibility that gametocyte infectivity may be related
to the duration of carriage of a less female biased sex ratio
was examined. Figure 3 is a Kaplan-Meier plot of the
cumulative probability of remaining a less female-biased
sex ratio free following treatment with amodiaquine dur-
ing the study periods. The probabilities were similar dur-
ing the periods of the study (Log rank statistic = 2, P =
0.37).
Table 2: Gametocyte carriage before and after treatment in 612 
children who completed 28-days follow up
Gametocyte carriage
Year No. At enrolment After treatment Total P value
2000 104 12 (11.5) 13 (12.5) 25 1.0
2004 388 38 (9.8) 29 (7.5) 67 0.31
2006 120 16 (13.3) 14 (11.7) 30 0.85
2000–2006 612 66 (10.8) 56 (9.2) 122 0.39
Table 3: Gametocyte density before and after amodiaquine treatment of the 612 children who completed 28-day follow-up
Year
Days of follow up Gametocyte density (/μL) 2000 2004 2006 2000–2006 P value
0 GM 13 (12) 16 (38) 17 (16) 16 (66) 0.66
Range 6 – 498 6 – 288 6 – 138 6 – 498
1 GM 13 (4) 17 (37) 24 (8) 18 (49) 0.85
Range 6 – 48 6 – 648 6 – 114 6 – 648
2 GM 21 (7) 20 (34) 35 (6) 21 (47) 0.77
Range 6 – 174 6 – 600 6 – 396 6 – 600
3 GM 18 (11) 25 (38) 19 (21) 23 (70) 0.75
Range 6 – 210 6 – 720 6 – 798 6 – 798
7 GM 10 (12) 32 (22) 22 (16) 22 (50) 0.3
Range 6 – 24 6 – 600 6 – 558 6 – 600
14 GM 11 (5) 14 (16) 11 (8) 13 (29) 0.7
Range 6 – 18 6 – 108 6 – 180 6 – 180
21 GM - 9 (4) 18 (1) 10 (5) 0.36
Range 6 – 12 18 6 – 18
2 8 G M - 1 2  ( 2 )5 7  ( 2 )2 6  ( 4 ) 0 . 8 2
Range 12 6 – 546 6 – 546
GM, geometric mean; Number in parenthesis indicates number of patientsMalaria Journal 2008, 7:169 http://www.malariajournal.com/content/7/1/169
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Relationship between gametocyte sex ratio and 
gametocytaemia or asexual parasitaemia
The percentage of male gametocytes was negatively corre-
lated with gametocyte density but not with asexual para-
site density (Spearman's r = -0.46, P < 0.0001 and r =
0.009, P = 0.94, respectively with n = 66 in both cases.
Risk factors associated with a male-biased gametocyte sex 
ratio
The pre-treatment factors associated with a male-biased
sex ratio are shown in Table 5. Age, gender or duration of
illness before presentation appeared not to be associated
with a male-biased sex ratio at enrolment. Absence of
fever, a haematocrit < 25%, asexual parasitaemia >
20,000/μL, gametocytaemia < 18/μL, and enrolment in
2006 were significantly associated with a male-biased sex
ratio at enrolment.
Following treatment, a haematocrit < 25% on days 0 and
7 and a parasitaemia greater > 20,000/μL of blood were
independent predictors of a male biased sex ratio 7 days
post initiation of treatment with amodiaquine (Table 6).
Discussion
The study showed continuing efficacy of amodiaquine
against asexual parasites, relative lack of gametocytocidal
effects, and peak gametocyte carriage occurring 3–7 days
after treatment commenced. The last finding is in contra-
distinction to that following treatment with artemisinin
derivatives or artemisinin-based combination therapy
where peak gametocyte carriage is seen pre-treatment in
children from this endemic area [7,10,24].
The average sex ratio of 0.076, is considerably lower than
those reported from Senegal (0.346) [25] or Cameroon
(0.22) [20]. Sex ratio increased over the relatively long
period but the causes are unclear. Exposure of these chil-
dren to sex ratio modifying influences, including antima-
larial drugs [13,26] may have been contributory. Sex ratio
may be positively correlated with gametocyte density in
animal infections [21,27] but in the present study was sig-
nificantly negatively correlated with gametocytaemia – a
finding similar to that from Senegal [25].
Although significant variations in sex ratio may occur in
natural populations [28,29], a consistent finding during
the entire period of the study was a significant shift in sex
ratio towards maleness by day 7 of initiation of treatment.
Indeed by this time, 29% of gametocytes were male. It
would appear anaemia was an important contributor to
gametocyte maleness and had resolved in many children
by day 7 (Figure 3). However, overall, the absence of low
gametocytaemia, which was expected to enhance gameto-
cyte maleness as a form of fertility insurance [30], and the
significantly increased gametocytaemia on day 7 (a possi-
ble effect of amodiaquine) suggest that by some as yet
unknown way, amodiaquine may encourage the develop-
ment of a less female-biased gametocyte sex ratio. A pos-
sible explanation is that amodiaquine or its metabolite
could exert different effects on male and female gameto-
cytes particularly if the gametocytes are exposed to the
metabolite for a long time. Perhaps by an effect on sex-
specific half-lives as has been previously reported for
pyrimethamine-sulfadoxine [13] but it is yet to be investi-
gated. Alternatively sequestered gametocytes with a less
female biased sex ratio could have been released during
this period. An interesting finding was the year to year var-
iation in sex ratio. The reasons for this are unclear but may
not be unrelated to environmental and other cues result-
ing in adaptive changes by the parasites.
Robert and others [25] found that in a population of
symptomatic and asymptomatic individuals, anaemia
and a wave of gametocytes were associated with signifi-
cant effects on sex ratio. In the present data set, five factors
were associated with increased risk of a less female biased
sex ratio at enrolment: absence of fever, anaemia, asexual
parasitaemia > 20,000/μL, low gametocytaemia and
enrolment in the year 2006. The differences in the risk fac-
tors between the present study and that of Robert et al [25]
clearly are due to differences in design. However, that
anaemia is associated with a less female biased sex ratio
may work in concert with other factors to promote the
Kaplan-Meier plot (survival curve) of cumulative probability  of remaining gametocyte-free after amodiaquine treatment of  malarious children in 2000 (thick broken line), 2004 (thin  broken line) and 2006 (solid line) (Log rank statistic = 0.8, P  = 0.23) Figure 1
Kaplan-Meier plot (survival curve) of cumulative probability 
of remaining gametocyte-free after amodiaquine treatment of 
malarious children in 2000 (thick broken line), 2004 (thin 
broken line) and 2006 (solid line) (Log rank statistic = 0.8, P 
= 0.23).
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Variations in the packed cell volume, density of gametocyte, and gametocyte sex ratio over the course of treatment of malaria  infections with amodiaquine in years 2000 (thick broken line), 2004 (thin broken line), and 2006 (solid line) Figure 2
Variations in the packed cell volume, density of gametocyte, and gametocyte sex ratio over the course of treatment of malaria 
infections with amodiaquine in years 2000 (thick broken line), 2004 (thin broken line), and 2006 (solid line).
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male biased sex ratio often observed following chemo-
therapy of the disease.
In lizard malaria parasite infections, high levels of parasi-
taemia are associated with a less female-biased sex ratio
[21]. In the cohorts of children, high levels of parasitae-
mia, which are common in young children in this
endemic area, were also found to be associated with a
male-biased sex ratio. This was not unexpected – high lev-
els of parasitaemia are associated with low gametocytae-
mia [14] – a relatively reduced risk of gametocyte carriage
and a factor that promotes gametocyte maleness as a form
of fertility insurance [30]. In addition, in areas of intense
transmission, such as ours, a less female biased sex ratio is
favoured [31] primarily because of multiplicity of infec-
tions, on the average the number of infecting clones in the
area is about 3–4 [32,33].
Absence of fever is associated with increased risk of game-
tocyte carriage [12,14,34]. It is unclear why afebrile chil-
dren should have an increased risk of male biased sex
ratio, and we have no explanation for our finding. Anae-
mia before, during, and after treatment was an important
predictor of a male biased sex ratio following treatment
with amodiaquine. This was expected and it supports the
suggestion that this factor may contribute to antimalarial-
associated gametocyte maleness. If artemisinin deriva-
tives, as has been proposed, selectively favour the emer-
gence of a female-biased sex ratio [7], it would now be
important to evaluate the predictors of male biased sex
ratio in children treated with different antimalarial drugs.
There is a need to justify the sex ratio regarded as male
biased in our study. Traditionally, sex ratio is assigned by
microscopy that often overestimated the proportion of
female gametocytes [35]. Therefore, regarding a sex ratio ≥
0.5 as male biased clearly shows a significantly male
biased ratio. Sex ratio can now be more accurately esti-
mated by a recently developed reverse-transcription
polymerase chain reaction techniques [36].
Table 4: Variations in mean gametocyte sex ratio with time after amodiaquine treatment of 612 children
Year
Days of follow up Sex ratio 2000 2004 2006 2000–2006 P value
0 Mean 0.004 (12) 0.048 (38) 0.2 (16) 0.076 (66) < 0.0001
SE 0.004 0.019 0.05 0.019
1 Mean 0.0 (4) 0.076 (37) 0.32 (8) 0.11 (49) 0.003
SE 0.0 0.025 0.12 0.03
2 Mean 0.13 (7) 0.1 (34) 0.25 (6) 0.13 (47) 0.3
SE 0.08 0.03 0.08 0.03
3 Mean 0.29 (11) 0.15 (38) 0.4 (21) 0.25 (70) 0.006
SE 0.1 0.03 0.08 0.04
7 Mean 0.25 (12) 0.25 (22) 0.37 (16) 0.29 (50) 0.48
SE 0.11 0.05 0.1 0.05
14 Mean 0.13 (5) 0.28 (18) 0.51 (6) 0.3 (29) 0.14
SE 0.08 0.08 0.14 0.06
21 Mean - 0.25 (4) 0.3 (1) 0.26 (5) -
SE - 0.25 - 0.19
28 Mean - 0.0 (2) 0.52 (2) 0.26 (4) 0.46
SE - 0.0 0.19 0.17
SE, standard error of mean; Number in parenthesis indicates number of patients
Kaplan-Meier plot (survival curve) of cumulative probability  of remaining free of a male-biased gametocyte sex ratio (gsr)  after amodiaquine treatment of malarious children in 2000  (thick broken line), 2004 (thin broken line) and 2006 (solid  line) (Log rank statistic = 2, P = 0.37) Figure 3
Kaplan-Meier plot (survival curve) of cumulative probability 
of remaining free of a male-biased gametocyte sex ratio (gsr) 
after amodiaquine treatment of malarious children in 2000 
(thick broken line), 2004 (thin broken line) and 2006 (solid 
line) (Log rank statistic = 2, P = 0.37).
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A limitation of the present study is that only gametocytae-
mia ≥ 10/μl were sexed. A limitation on the predictors of
less female biased sex ratio is the inability to evaluate
other potential predictors such as treatment with other
gametocyte sex ratio modifying drugs such as pyrimeth-
amine-sulphadoxine, trimethoprim-sulphamethoxazole
[13,25]. This will be examined in an ongoing study. How-
ever, the present results are strengthened by the use of a
consistent protocol over the entire study period; the 6.5
year-long period allowed the factoring of time into the
analysis and to gain some insight into the evolution of a
less female biased gametocyte sex ratio in our area of
study, in a manner similar to our observations on the evo-
lution of drug resistance in our study area [37].
Conclusion
Amodiaquine may significantly increase gametocyte car-
riage, density and sex ratio in African children treated for
Table 5: Risk factors for a male-biased gametocyte sex ratio at presentation in children with uncomplicated falciparum malaria, 
showing the crude odd ratios (OR) and their 95% confidence intervals (CI)
Variables Total Number No with gsr ≥ 0.5 OR (95% CI) P value
Gender
male 37 2 1
female 29 3 2 (0.4 – 9.8) 0.45
Age
< 5 years 29 1 1
> 5 years 37 4 3.4 (0.36 – 32) 0.26
Duration of illness
≤ 3 days 54 5 1
≥ 3 days 12 0 0.9 (0.8 – 1) 0.16
Fever*
afebrile 29 5 1
febrile 36 0 0.8 (0.7 – 1) 0.01
Packed cell volume
≤ 25% 11 3 1
≥ 25% 43 2 0.1 (0.02 – 0.9) 0.02
Parasitaemia
≤ 20,000 μl/l 33 0 1
> 20,000 μl/l 33 5 1.2 (1 – 1.4) 0.02
Gametocytaemia
< 18 μl/l 38 5 1
≥ 18 μl/l 28 0 0.8 (0.7 – 1) 0.04
Year
Pre 2006 50 1 1
2006 onwards 16 4 16 (1.7 – 159.7) 0.002
*Fever, body temperature ≥ 37.5°CMalaria Journal 2008, 7:169 http://www.malariajournal.com/content/7/1/169
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Table 6: Risk factors for a male-biased gametocyte sex ratio 7 days after amodiaquine treatment of children with uncomplicated 
falciparum malaria, showing the crude and adjusted odd ratios (OR) and their 95% confidence intervals (CI)
Variables Total Number No with gsr ≥ 0.5 OR (95% CI) P value AOR (95% CI) P value
Gender
male 25 7 1
female 25 8 1.1 (0.6 – 2) 0.75 - -
Age
< 5 years 20 7 1
≥ 5 years 30 8 0.8 (0.5 – 1.4) 0.5 - -
Duration of illness
≤ 3 days 38 12 1
> 3 days 12 3 0.8 (0.2 – 2.5) 0.67 - -
Fever*
afebrile 21 6 1
febrile 29 9 1.1 (0.6 – 1.7) 0.85 - -
PCV (day 0)
< 25% 6 5 1 1
≥ 25% 44 10 0.6 (0.5 – 1) 0.002 0.06 (0.006 – 0.7) 0.03
Parasitaemia (day 0)
≤ 20,000 μl/l 22 3 1 1
> 20,000 μl/l 28 12 1.8 (1.1 – 2.7) 0.025 5.7 (1 – 33) 0.05
Gametocytaemia (day 0)
< 18 μl/l 11 4 1
≥ 18 μl/l 17 7 1.1 (0.6 – 2) 0.8 - -
Year
pre 2006 34 8 1
2006 16 7 1.8 (0.8 – 4) 0.15 - -
GSR (day 0)
< 0.5 26 10 1
≥ 0.5 2 1 1.5 (0.1 – 22) 0.75 - -
FCT
< 2 days 33 10 1
≥ 2 days 2 1 2.2 (0.1 – 32) 0.56 - -
PCT
< 3 days 32 8 1
≥ 3 days 18 7 1.5 (0.7 – 3.1) 0.3 - -
PCV (day 7)
< 25% 4 3 1 1
≥ 25% 46 12 0.8 (0.6 – 3.7) 0.04 0.06 (0.003 – 1) 0.05
Re-parasitaemia
Absent 44 14 1
Present 6 1 0.5 (0.06 – 3.7) 0.45 - -
*Fever, body temperature ≥ 37.5°C; FCT, fever clearance time; GSR, gsr, gametocyte sex ratio; PCV, packed cell volume; PCT, parasite clearance 
timeMalaria Journal 2008, 7:169 http://www.malariajournal.com/content/7/1/169
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falciparum malaria, and may potentially influence trans-
mission. It is also possible that anaemia could have con-
tributed to the less female biased sex ratio.
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